. . . . . "Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors."@en . . . "Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis."@en . . . . "Humans and other mammals"@en . . . . "investigational"@en . "212141-54-3"@en . . . . . . . "PTK 787"@en . . . . . . " "@en . "PTK/ZK"@en . "Vatalanib"@en . . "Approximately 6 hours."@en . "# Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17584317 # Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17616257 # Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16882767"@en . . . . "Rapid onset of absorption"@en . . "1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate"@en . . "Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC)."@en . . . . .